Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

NCT03302403 is registered in ClinicalTrials.gov with Kang YU as lead sponsor.

NCT NCT03302403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03302403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
Lead sponsor
Kang YU
Phase
Not applicable
Overall status
Unknown status
Start date
December 29, 2017
Completion date
December 12, 2023
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of esophagogastric junction, b cell leukemia, b cell lymphoma, hepatocellular carcinoma, myeloma, pancreatic carcinoma